The Emergence of Radiopharmaceuticals

With advances in targeted cancer therapies and precision medicine, radiopharmaceuticals have emerged as a rapidly evolving area of the pharmaceutical industry. Radiopharmaceuticals combine radioactive isotopes with biologically targeted molecules to deliver radiation directly to tumor cells.¹ This sector is attracting significant investment and strategic collaborations across major pharmaceutical companies.

Radiopharmaceuticals contain radioactive isotopes used for both diagnostic and therapeutic purposes.¹ Traditionally used in imaging, such as PET and SPECT scans, the field has expanded into therapeutic applications that deliver targeted radiation to cancer cells. This capability has provided a precision medicine pathway in oncology where treatment can be personalized based on diagnostic imaging. By linking monoclonal antibodies with radioactive isotopes, companies can precisely target tumor cells while sparing healthy tissue. This approach represents a significant advancement over traditional chemotherapy and radiation therapy, which can affect both cancerous and non-cancerous cells. As a result, radiopharmaceuticals are considered a promising modality for treating difficult-to-target cancers, particularly solid tumors.

Novartis has established a dominant position with Lutathera as well as its blockbuster radiopharmaceutical therapy Pluvicto. Pluvicto is indicated for a specific type of metastatic castration-resistant prostate cancer.² Pluvicto’s commercial success has sparked competitor interest in pursuing radioligand R&D efforts to develop similar or next-generation therapies to compete in this treatment market.³

In addition, an indicator of the radiopharmaceutical sector’s growth is the increasing number of strategic partnerships as well as mergers and acquisitions (M&As) activity. In April 2026, Regeneron Pharmaceuticals entered into a collaboration with Telix Pharmaceuticals to co-develop and co-commercialize next-generation radiopharmaceutical therapies.⁴ Through 2023 and 2024, Bristol Myers Squibb acquired RayzeBio, AstraZeneca acquired Fusion Pharmaceuticals, and Eli Lilly acquired Point Biopharma.^5,6,7 These transactions reflect a strategic push by large pharmaceutical companies to secure capabilities in radiopharmaceutical development and manufacturing and display the long-term growth potential of the sector. 

The global radiopharmaceuticals market has demonstrated strong growth. Projections suggest that the market will reach $21.8 billion by 2033, which is driven by increasing demand for targeted cancer therapies and advancements in nuclear medicine.⁸ Along with prostate cancer, the field is expanding into other solid tumors and hematologic cancers.¹ This growth trajectory underscores the significant commercial potential of radiopharmaceuticals and reinforces the increase in investment and strategic activity across the industry.

Despite its promise, the radiopharmaceutical sector faces several critical challenges. One of the most pressing issues is the fragility of the supply chain for key radioactive isotopes. They have short half-lives, making them difficult to produce, transport, and store. In addition, there is a shortage of specialized talent in areas such as radiochemistry, nuclear medicine, and clinical development. These constraints can slow down research, limit manufacturing capacity, and create barriers to widespread adoption. At the same time, the radiopharmaceutical industry is undergoing a period of rapid transformation driven by scientific innovation, strategic investment, and growing demand for targeted cancer therapies. High-profile partnerships and increased M&A activity are reshaping the competitive landscape. The sector’s strong growth trajectory and expanding clinical applications offer a promising future. As pharmaceutical companies continue to invest and innovate, radiopharmaceuticals are poised to play an increasingly important role in the fight against cancer.

References:

1. Khalaji A, Rostampour M, Riahi F, et al. The Use of Radiopharmaceuticals in Targeted Cancer Therapy: A Narrative Review. Int J Physiol Pathophysiol Pharmacol. 2025;17(2):37-44.
2. Highlights of Prescribing Information. Pluvicto FDA Package Insert. 2022.
3. Armstrong A. Novartis’ Pluvicto Heavywork Proves Radiopharma Can Succeed. Biospace. 2025.
4. Regeneron Pharmaceuticals. Regneron and Telix Announce Strategic Collaboration. Regeneron Press Release. 2026.
5. Bristol Myers Squibb. Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio. Bristol Myers Squibb Press Release. 2023.
6. AstraZeneca. Acquisition of Fusion Completed. AstraZeneca Press Release. 2024.
7. Eli Lilly and Company. Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies. Eli Lilly Press Release. 2023.
8. Yahoo Finance PR Newswire. Radiopharmaceuticals Market to Reach $21.8 Billion by 2033 Globally, at 10.6% CAGR: Allied Market Research. 2026.

*Information presented on RxTeach does not represent the opinion of any specific company, organization, or team other than the authors themselves. No patient-provider relationship is created.